Company Snapshot
- Ticker
- DXCM
- Name
- DXCM
- Sector
- None
- Currency
- 0
- Relative Volume
- None
- Market Cap
- 26188056000.000000
- Volume
- 6,833,025
- Avg Volume (3M)
- 5,821,480
DXCM
DXCM
Last update recent
66.96
-1.98
(-2.87%)
Market Cap
26188056000.000000
Dividend Yield
0.00%
1Y Return
None%
Beta
None
Price & Moving Averages
Interactive chart with SMA overlays and intraday breadth.
Profitability
- Revenue
- 4515900000.000000
- EPS
- 1.85
- Dividend / Share
- None
- Total Dividends
- $0.00
- Dividend Yield
- 0.0%
- Net Income
- 720700000.000000
- Net Margin
- 15.96%
- Payout Ratio
- 0.0%
- Qtly Growth YoY
- None
Valuation & Quality
- P/E
- 36.34
- Forward P/E
- None
- P/S
- 5.80
- P/B
- 9.61
- Beta
- None
- Debt / Equity
- 0.92
- Current Ratio
- 1.56
- Return on Equity
- 0.26%
- Return on Assets
- 0.10%
Technicals & Returns
- Distance vs 200 DMA
- -10.12%
- 200 DMA
- 74.50
- Distance vs 50 DMA
- 4.46%
- 50 DMA
- 64.10
- Return 1Y
- None%
- Return YTD
- None%
- Beta (Trailing)
- None
- Relative Volume
- None
Factor Lens
Plot valuation, momentum, or volume trends.
Seasonal Performance
Company Overview
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom Real-Time API, which enables invited third-party developers to integrate real-time CGM data into their digital health applications and devices; Dexcom ONE, that is designed to replace finger stick blood glucose tes Read more
- Name
- DXCM
- Industry
- Medical - Devices
- CEO
- Mr. Kevin Ronald Sayer
- Employees
- 9,500
- IPO Date
- 2005-04-14
- Phone
- 858 200 0200
- Address
- None
- Website
- https://www.dexcom.com
Dividend Yield
0.00%
TTM Distributions
$0.00
Latest News
Curated headlines from premium sources.
DXCM Deadline: DXCM Investors with Losses in Excess of $100K Have Opportunity to Lead DexCom, Inc. Securities Fraud Lawsuit
NEW YORK , Dec. 15, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of DexCom, Inc. (NASDAQ: DXC…
DXCM Investors Have Opportunity to Lead DexCom, Inc. Securities Fraud Lawsuit with the Schall Law Firm
LOS ANGELES, Dec. 15, 2025 (GLOBE NEWSWIRE) -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit…
Contact The Gross Law Firm by December 26, 2025 Deadline to Join Class Action Against DexCom, Inc.(DXCM)
NEW YORK , Dec. 15, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of DexCom, Inc. (NASDAQ: DXCM). Shareholders who purcha…
DXCM DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages DexCom, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important December 29 Deadline in Securities Class Action - DXCM
New York, New York--(Newsfile Corp. - December 14, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of DexCom, …
DXCM CLASS ACTION ALERT: Kessler Topaz Meltzer & Check, LLP Reminds DexCom, Inc. Shareholders of Securities Fraud Class Action Lawsuit
RADNOR, Pa. , Dec. 14, 2025 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that securities class action l…
DXCM DEADLINE: ROSEN, A RANKED AND LEADING LAW FIRM, Encourages DexCom, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important December 29 Deadline in Securities Class Action – DXCM
NEW YORK, Dec. 13, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of DexCom, Inc. (NASDAQ: D…